Article
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
The Journal of clinical investigation - 1 Jul 2009
Jones Joanne L, Phuah Chia-Ling, Cox Amanda L, Thompson Sara A, Ban Maria, Shawcross Jacqueline, Walton Amie, Sawcer Stephen J, Compston Alastair, Coles Alasdair J
Abstract excerpt
Phase II clinical trials revealed that the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath-1H) is highly effective in the treatment of early relapsing-remitting multiple sclerosis. However, 30% of patients develop autoimmunity months to years after pulsed exposure to alemtuzumab, usually targeting the thyroid gland and, more rarely, blood components. In this study, we show that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.